Genomics technologies such as next-generation sequencing (NGS) and microarrays are accelerating neurogenomics research by revealing the mechanisms behind complex neurological diseases such as Alzheimer’s disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and psychiatric disorders.
The interplay between heritable and nonheritable mutations, epigenetics, and other factors requires NGS-level analyses to increase our understanding. Arrays facilitate large-scale studies of genetic variants associated with neurological diseases. Illumina offers the NGS and microarray tools needed to make genomic neuroscience research possible.
TruSeq Neurodegeneration Panel: This NGS panel covers 118 risk genes associated with common neurodegenerative diseases, including Alzheimer’s disease, Parkinson's disease, ALS, and others.
Infinium PsychArray BeadChip: This array allows researchers to evaluate genetic variants associated with common psychiatric disorders.
Neuro Consortium Array: Researchers in the neurogenomics community contributed content for this high-density array featuring over 180,000 markers associated with common neurodegenerative diseases.
Kailos Complete Pharmacogenetic Panel: This enrichment-based targeted sequencing research panel covers 43 genes associated with responses to ~100 medications.
See how the TruSeq Neurodegeneration Panel helps researchers investigate the genetic landscape of Alzheimer's, Parkinson's, and other neurological diseases.
Learn how integrating whole-genome or whole-exome sequencing data with transcriptome information (from RNA-Seq) and epigenetic information (from methylation arrays) in stem cells and tissue types of interest can help identify genes and pathways that have a role in neurological diseases.
View WebinarNeuroscience researchers use NGS to identify variants for a microarray designed for ADHD, autism, and schizophrenia studies.
Read InterviewExperts discuss the genetics of dementia in this podcast episode, hosted by the UK Dementia Research Institute and Illumina.
Listen NowDr. Franco Taroni uses targeted sequencing to uncover novel genomic variants associated with metabolic and neurological disorders.
Read InterviewDr. Jacob Michaelson, Associate Professor of Psychiatry at the University of Iowa, discusses how he uses genomic and computational techniques to study autism and other psychiatric disorders.
Listen NowDr. Michael R. Wilson, Assistant Professor of Neurology at the University of California San Francisco, discusses how genomics can shed light on causes of brain inflammation.
Listen NowDr. Ted Abel, Director of the Iowa Neuroscience Institute, discusses transcriptional and epigenetic changes associated with long-term memory.
Listen NowUnderstand how variations in the human genome affect our response to medications. Pharmacogenomics (PGx) research can ultimately help maximize the benefits of treatment plans while reducing health care costs.
Learn MoreGenomic technologies are introducing new avenues for understanding complex disease etiology on a molecular level.
Learn MoreWhole-genome sequencing and other genomic technologies can help scientists identify genetic variants linked to rare disorders.
Learn MoreJonathan Mill, PhD and his team use genomics to better understand neuropsychiatric diseases.
Target enrichment captures genomic regions of interest by using hybridization to target-specific biotinylated probes.
Jan Veldink, PhD shares how integrative genomics helped drive his ALS research and identify NEK1 as an ALS gene.